Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
LOW-FLOAT-==>>=-$$$_679-MILLION__LOW__FLOAT->>--->>>>>-https://www.otcmarkets.com/stock/GXXM/news/story?e&id=2457748
GXXM featured:- https://microcapdaily.com/gex-consulting-inc-otcmkts-gxxm-accumulation-grows-dilution-slows-equity-investments-balloon/
$$$_CHEAP_***AI***_LOW__FLOAT-STOCK-->>$GXXM-https://www.otcmarkets.com/stock/GXXM/security
LOW-FLOAT-==>>=-$$$_679-MILLION__LOW__FLOAT->>--->>>>>-https://www.otcmarkets.com/stock/GXXM/news/story?e&id=2457748
GXXM featured:- https://microcapdaily.com/gex-consulting-inc-otcmkts-gxxm-accumulation-grows-dilution-slows-equity-investments-balloon/
$$$_CHEAP_***AI***_LOW__FLOAT-STOCK-->>$GXXM-https://www.otcmarkets.com/stock/GXXM/security
LOVE IT- VERY NICE- ROCK AND ROLLING $DBMM
BS POST- DO DAMN WHAT? AND THE UNITED STATES INDEPENDENCE WAS HUNDREDS OF YEARS AGO AND YET ON JULY 4TH THERE WILL BE LOTS OF EXCITEMENT AND CELEBRATIONS
WHAT'S THE POINT OF THE POST. EMMM - NO POINT RIGHT?
THANKS FOR SHARING BOOOOOM- GO $DBMM
WOW-$PPCB KNOWN IN THE PHARMA WORLD-https://medilodgeoffrankenmuth.com/announcement/propanc-pancreatic-treatment-meets-fda-milestone/
CANCER DRUG PUBLICATION-**SEE BOTTOM OF PAGE 9**-https://www.aop-health.com/_Resources/Persistent/a/5/5/e/a55e4121f127492f6d097d038294085f976fd354/CDN_Issue_733.pdf
Propanc Biopharma Targets Pancreatic & Ovarian Cancers for PRP Clinical Studies with Combined Markets to Reach Over $14.3 Billion by 2027
Propanc Biopharma, Inc. (OTC Pink: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company developing novel cancer treatments for patients suffering from recurring and metastatic cancer, today announced that Chief Scientific Officer and Co-Founder, Dr Julian Kenyon, MD, MB, ChB, explains why pancreatic and ovarian cancers are selected as the primary target therapeutic indications for planned PRP human studies. According to Dr Kenyon, target indications were selected based on in vitro and in vivo data, as well as clinical observations from a compassionate use study investigating the effects of two proenzymes, trypsinogen and chymotrypsinogen against a range of malignant tumors. Overall, proenzymes appeared to exert significant effects against more aggressive, less differentiated tumor types, like pancreatic and ovarian tumors. Patients from the compassionate use study suffering from cancers of the GI tract, or endocrine tumors, such as pancreatic and ovarian cancers, benefited most from treatment. The world market for pancreatic and ovarian cancer drugs is projected to grow to $4.2 Billion in 2025 according to Grandview Research and $10.1 Billion by 2027 according to iHealthcareAnalyst, respectively, resulting in a combined global market of $14.3 Billion over the next 5-year period.
ADVERTISEMENT
Extensive laboratory analysis confirmed that PRP reduced the main characteristics of cancer spread, namely angiogenesis (blood vessel formation), which is a critical step in tumor development, as well as the spreading of tumor metastases. In addition, assays revealed that the migration capacity of ovarian, pancreatic, melanoma and colon cancer cells was suppressed after incubation with PRP. Furthermore, evidence suggests the epithelial to mesenchymal transition (EMT), a biological process associated with wound healing and cell migration, which causes cancer stem cells (CSCs) to become motile and invasive, is associated with metastasis and inducing drug resistance in many cancers, such as pancreatic and ovarian cancers. Studies in pancreatic and cancer cell lines after PRP treatment demonstrated a significant reduction in EMT markers and genes and in fact, a reversal of the EMT process so that CSCs become benign and less resistant to standard treatments.
ADVERTISEMENT
The in vivo effects of PRP at different doses on tumor weight in implanted pancreatic and ovary tumors was evaluated. In the pancreatic tumor model, there was significant reduction in mean tumor weight in animals treated for 26 days with PRP with more than 85% tumor growth inhibition compared with the control. Furthermore, ovary tumor-bearing mice showed a significant reduction in mean tumor weight in animals treated for 21 days with two different doses of PRP, resulting in a 46 – 52% tumor growth inhibition compared with the control.
The clinical efficacy of a suppository formulation containing bovine pancreatic proenzymes trypsinogen and chymotrypsinogen was evaluated in the context of a UK Pharmaceuticals Special Scheme and the results were published in Scientific Reports. Clinical effects were studied in 46 patients with advanced metastatic cancers of different origin (prostate, breast, ovarian, pancreatic, colorectal, stomach, non-small cell lung, bowel cancer and melanoma) after treatment with a rectal formulation of both pancreatic proenzymes. No severe or serious adverse events related to the rectal administration were observed. Patients did not experience any hematological side effects as typically seen with classical chemotherapy regimens.
ADVERTISEMENT
In order to assess the therapeutic activity, overall survival of patients under treatment was compared to the life expectancy assigned to a patient prior to treatment start. Nineteen from 46 patients (41.3%) with advanced malignant diseases, most of them suffering from metastases, had a survival time significantly longer than their expected, in fact, for the whole set of cancer types, mean survival (9.0 months) was significantly higher than mean life expectancy (5.6 months). In the case of pancreatic and ovarian cancers, 2 from 4 pancreatic cancer patients and 4 from 7 ovarian cancer patients significantly exceeded life expectancy.
ADVERTISEMENT
As a result of the extensive studies undertaken, particularly in pancreatic cancer, the Company applied for and received Orphan Drug Designation (ODD) from the US Food and Drug Administration (USFDA) for the use of its lead product, PRP, for the treatment of pancreatic cancer. The approved indication is one of the most lethal malignancies with a median survival of 6 months and a 5-year survival rate of less than 5%. The lethal nature of this disease stems from its propensity to rapidly disseminate to the lymphatic system and distant organs, and is a major unmet medical issue. Under the Orphan Drug Act (ODA), drugs, vaccines, and diagnostic agents qualify for orphan status if they are intended to treat a disease affecting less than 200,000 American citizens. Under the ODA, orphan drug sponsors qualify for seven-year FDA-administered market Orphan Drug Exclusivity (ODE), tax credits of up to 50% of R&D costs, R&D grants, waived FDA fees, protocol assistance and may get clinical trial tax incentives.
ADVERTISEMENT
“Over the past 15 years, our extensive research has uncovered a truly unique and exciting technology that selectively targets and eradicates cancer stem cells, whilst leaving healthy cells alone, making it less toxic compared with standard treatment approaches,” said Dr Kenyon. “Furthermore, our technology appears to be effective against more aggressive, less differentiated tumor types where few treatment options exist, and prognosis is poor, especially in the case of pancreatic and ovarian cancers. I look forward to advancing PRP to human studies where we can fully assess the clinical efficacy of PRP in a controlled setting.”
Propanc plans to undertake a First-In-Human study in 30 to 40 advanced cancer patients suffering from solid tumors to determine a maximum tolerated dose for PRP treatment, followed by two proof of concept studies in pancreatic and ovarian cancers, 60 patients in each study, to confirm the clinical efficacy of PRP in the selected target therapeutic indications.
PRP is a mixture of two proenzymes, trypsinogen and chymotrypsinogen from bovine pancreas administered by intravenous injection. A synergistic ratio of 1:6 inhibits growth of most tumor cells. Examples include kidney, ovarian, breast, brain, prostate, colorectal, lung, liver, uterine and skin cancers.
About Propanc Biopharma, Inc.
Propanc Biopharma, Inc. (the “Company”) is developing a novel approach to prevent recurrence and metastasis of solid tumors by using pancreatic proenzymes that target and eradicate cancer stem cells in patients suffering from pancreatic, ovarian and colorectal cancers. For more information, please visit www.propanc.com.
The Company’s novel proenzyme therapy is based on the science that enzymes stimulate biological reactions in the body, especially enzymes secreted by the pancreas. These pancreatic enzymes could represent the body’s primary defense against cancer.
To view the Company’s “Mechanism of Action” video on its anti-cancer lead product candidate, PRP, please click on the following link: http://www.propanc.com/news-media/video
TINY BABY .006 ASK ABOUT TO BE GONE-FLASHING NEXT ON L2 SEEING .0075--3 CENTS
DON'T UNDERSTAND THE SCORE CARD ASPECT OF THE POST- PLEASE ELABORATE
THANKS
GO $DBMM
WITH OVER 1.2 BILLION SHARES YESTERDAY- WHAT HAPPENED TO THEM?
WILL BE TAKING A BREAK FROM HERE FOR A LITTLE WHILE
OVER AND OUT
$GXXM NICE CLEAN L2
000'S-679-MILLION-LOW--FLOAT-$$$_CHEAP__LOW__FLOAT->-->>>>>--->>-$GXXM-https://www.otcmarkets.com/stock/GXXM/security
000'S-679-MILLION-LOW--FLOAT-$$$_CHEAP__LOW__FLOAT->-->>>>>--->>-$GXXM-https://www.otcmarkets.com/stock/GXXM/security
L2 SHOWING TINY ..006 ASK-GETS EATING UP-THEN .0073- WEEEEEEE AND UP UP AHAHAHAAA
$DBMM
$DBMM=====>>>-.03 CENTS ON L2 ASK=====-.03-CENTS--ON--L2==ASK-WEEEEEEEEEEEE
ROFL- HEY DUDE - $DBMM SHORT SQUEEZE STARTING?- WEEEEEEEE
AWESOME
AHAHAHAHAHAHA
THAT'S WONDERFUL
$PPCB
LOOKING FORWARD PENNY BREAKOUT WITH $ICBU
DOING SOME DD ON THE $ICBU & CUDO VENTURES DEAL AND ALL I CAN SAY IS WOW
$ICBU BIG THINGS COMING
HELLO AND GOOD MORNING $PPCB
GOOD MORNING $GXXM
$$$_CHEAP_***AI***_LOW__FLOAT-STOCK-->>$GXXM--->>>>>-$GXXM--->>-$GXXM-https://www.otcmarkets.com/stock/GXXM/security
$$$_CHEAP__LOW__FLOAT->>$GXXM--->>>>>-https://www.otcmarkets.com/stock/GXXM/news/story?e&id=2457748
$$$_CHEAP_***AI***_LOW__FLOAT-STOCK-->>$GXXM--->>>>>-$GXXM--->>-$GXXM-https://www.otcmarkets.com/stock/GXXM/security
$$$_CHEAP__LOW__FLOAT->>$GXXM--->>>>>-https://www.otcmarkets.com/stock/GXXM/news/story?e&id=2457748
LMAO-BUT SHORT POSITIONS OUT OF AMO- DUDE
TIME FOR $DBMM SHORT SQUEEZE ALERT?
AHAHAHAHAHAHAAAA
$DBMM AQUISITIONS COMING - $$$
$$$_CHEAP_***AI***_LOW__FLOAT-STOCK-->>$GXXM--->>>>>-$GXXM--->>-$GXXM-https://www.otcmarkets.com/stock/GXXM/security
$$$_CHEAP__LOW__FLOAT->>$GXXM--->>>>>-https://www.otcmarkets.com/stock/GXXM/news/story?e&id=2457748
$$$_CHEAP_***AI***_LOW__FLOAT-STOCK-->>$GXXM--->>>>>-$GXXM--->>-$GXXM-https://www.otcmarkets.com/stock/GXXM/security
$$$_CHEAP__LOW__FLOAT->>$GXXM--->>>>>-https://www.otcmarkets.com/stock/GXXM/news/story?e&id=2457748
GOOD TO SEE YA TOO- SOUNDS GOOD TO ME - $PPCB
$ICBU NOW OTC CURRENT-BIG THINGS COMING- WEEEEEEEE
IRRELEVANT BS- THAT BS NARRATIVE IS NOT EXCEPTION FOT $ICBU- IT’s THE SAME BS NARRATIVE FOR $ICBU TYPE PLAYS THE BREAKOUT 1000% ALL THE TIME
YES INDEED $GXXM
$PPCB FDA ORPHAN DRUG APPROVED?—-AMAZING AND REALLY BIG DEAL
FILINGS**NOW-***OTC-CURRENT***-CRYPTO STOCK-ALERT-$$$$-https://www.nasdaq.com/press-release/imd-companies-announces-partnership-with-cudo-ventures-the-global-leader-in-providing
ALERT-CRYPTO-STOCK-$ICBU NOW OTC CURRENT -https://www.otcmarkets.com/stock/ICBU/security
IT SEEMS SOMETHING AMAZING IS ON THE WAY
FILINGS**NOW-***OTC-CURRENT***-CRYPTO STOCK-ALERT-$$$$-https://www.nasdaq.com/press-release/imd-companies-announces-partnership-with-cudo-ventures-the-global-leader-in-providing
ALERT-CRYPTO-STOCK-$ICBU NOW OTC CURRENT -https://www.otcmarkets.com/stock/ICBU/security
IT SEEMS SOMETHING AMAZING IS ON THE WAY
GOOD MORNING $PPCB
I THINK IT’s ABSOLUTELY AMAZING THAT THIS COMPANY HAS ORPHAN DRUG APPROVAL.
VERY RARE TO SEE BIOTECH/PHARMACEUTICAL COMPANY WITH SUCH A STATUS TRADING AT SUCH A DIRT CHEAP PRICE
$PSRU_BREAKOUT_COMING_>>___$PSRU__$PSRU__$PSRU